Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia (Q35184848)

7 August 2017

1 reference

title

Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia (English)

1 reference

7 August 2017

1 reference

1 reference

coronary artery disease

1 reference

1

Jaakko Tuomilehto

0 references

publication date

1 July 2003

1 reference

Diabetes Research and Clinical Practice

7 August 2017

1 reference

7 August 2017

61 Suppl 1

1 reference

7 August 2017

S27-34

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

1 reference

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Management of dyslipidemia in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900125-6

7 January 2021

10.1016/S0168-8227(03)00125-6

Identifiers

DOI

1 reference

release_h2pkyxp7lrfd7oleq7pacasxua

7 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h2pkyxp7lrfd7oleq7pacasxua

24 November 2022

mapped directly with Wikidata item

PubMed ID

12880692

1 reference

PubMed ID

12880692